Latest Vioxx verdict is win number five for Merck

Share this article:
Merck has been cleared of responsibility in the heart attack of a former Vioxx patient in the 10th case to go to trial over the withdrawn painkiller. The latest verdict brings the trial tally to five wins and four losses for Merck. A new trial was granted for the remaining verdict in New Jersey last month, following the emergence of new data in that case. In the latest case, a federal jury in New Orleans ruled Merck had adequately warned of Vioxx’s heart risks and stated that Vioxx wasn’t the cause of the heart attack of Robert Smith, 56, of Florence, KY. Merck withdrew Vioxx from the market after a study linked the drug to heart risks two years ago this week.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Novartis apologizes for slow reporting

Novartis is apologizing to Japan after the Ministry of Health, Labor and Welfare said the company had dragged its feet reporting adverse events for two of its cancer drugs.

J&J pulls morcellator from market

The company is calling the move a withdrawal, as opposed to a recall.

Pfizer buys two Baxter vaccines

The meningitis and encephalitis medications earned a combined $300 million last year.